What cancer does Lorlatinib treat?

Lorlatinib/Lorlatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) positive as measured by an FDA approved test.

Lorlatinib/Lorlatinib is a kinase inhibitor with in vitro activity against ALK and ROS1andTYK1, FER, FPS pan>, TRKA, TRKB, TRKC, FAK, FAK2 and ACK activities. Lorlatinibhas shown activity in vitro against multiple mutated forms of the ALKenzyme, including some mutations detected in tumors undergoing disease progression with crizotinib and other ALK inhibitors.

Lorlatinib/lorlatinibThe recommended dose is 100 mg orally, once daily. Patients with severe renal impairment: 75 mg orally once daily. The most common (incidence≥20%)adverse reactions and Grade 3-4 laboratory abnormalities with lorlatinib are edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, dyspnea, arthralgia, diarrhea, mood effects, hypercholesterolemia, hypertriglyceridemia, and cough. Larlatinib has been associated with embryonic-fetal toxicity, can cause fetal harm, informs women of reproductive potential of potential risks to the fetus, recommends men and women of childbearing potential to use effective non-hormonal contraceptive methods. Assess fasting blood glucose before initiating lorlatiniband periodically during treatment, if not adequately controlled with optimal medical management, discontinuelorlatinib and then consider dose reduction or permanent discontinuation based on severity. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.

xa0